title: [Involved-field three-dimensional conformal radiation treatment for stage III non-small-cell lung].
abstract: OBJECTIVE
  To investigate the feasibility of involved-field irradiation (IFI ) for stage III non-small cell lung cancer (NSCLC).
  
  
  METHODS
  From September 1997 to November 2001, 200 stage-III NSCLC patients were randomly divided into two groups-- IFI and ENI (elective node irradiation). The IFI group was irradiated by 3DCR to a dose of 68-74 Gy/34-37f/7-9 w including the primary tumor and the lymph nodes of > or = 10 mm in short axis. The ENI group was irradiated to a dose of 60-64 Gy/30-32f/6-7.5 w including the primary tumor, ipsilateral hilum, subcarinal and mediastinal lymph nodes, even the supraclavicular area when the lymph nodes of superior mediastinum were involved.
  
  
  RESULTS
  The overall response (CR + PR) rates were 90.0% in IFI group and 79.0% in ENI group. Radiation pneumonitis developed in 29.0% of the patients in ENI group and 17.0% in IFI group (P = 0.04). The 1-year primary tumor failure rate in IFI group (13.0%) was lower than that (23.0%) in ENI group. The 1-year involved nodal failure rate was 20.0% in ENI group and 10.0% in IFI group (P = 0.048). The 1-year elective node failure rate was 16.0% in ENI group versus 21.0% in IFI group (P = 0.39). The 1-, 2-and 3-year overall survival rate was 67.2% , 38.7% , 27.3% , respectively, in IFI group; versus 59.7% , 25.6% , 19.2% in ENI group, with a difference significant in the 2-year overall survival rate between IFI and ENI group (P = 0.048).
  
  
  CONCLUSIONS
  Involved-field 3D-CRT for stage-III non-small cell lung cancer is well tolerated. It does not increase the rate of lymph node failure in the elective node irradiation field, and may improve the survival due to dose escalation.
authors.affiliation: Department of Radiation Oncology, Shandong Cancer Hospital, Jinan 250117, China.
authors.forename: Jin-Ming
authors.initials: JM
authors.lastname: Yu
authors.forename: Xin-Dong
authors.initials: XD
authors.lastname: Sun
authors.forename: Ming-Huan
authors.initials: MH
authors.lastname: Li
authors.forename: Jian-Dong
authors.initials: JD
authors.lastname: Zhang
authors.forename: Chun-Ping
authors.initials: CP
authors.lastname: Yao
authors.forename: Sen
authors.initials: S
authors.lastname: Liu
authors.forename: Zhen
authors.initials: Z
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology / Q000532:radiotherapy*; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D015182:Lymphatic Irradiation / Q000379:methods*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011879:Radiotherapy Dosage; D020266:Radiotherapy, Conformal / Q000379:methods*; D012074:Remission Induction; D016019:Survival Analysis; D016896:Treatment Outcome